EGFR and neoplasm: In vivo results showed in two different tumor models durable responses at lower doses compared to diABZI with increased tumor‐localized inflammatory cytokines.[111] The cGAMP analogue IMSA172 conjugated to an anti‐EGFR binding antibody led to suppression of B16‐F10 tumor growth dependent on the expression of EGFR.